Large gap with delayed quotes
|
Last quote
08/30/2025
-
02:00:00
|
Bid
08/29/2025 -
21:59:59
|
Bid Volume |
Ask
08/29/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
11.355
-0.245
(
-2.11% )
|
11.35
|
23,400 |
11.36
|
2,300 |
Analysis date: 29.08.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 01.07.2025.
Interest
Weak
Weak
Two stars since 26.08.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 29.04.2025 at a price of 8.20.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 26.08.2025.
4wk Rel Perf
-10.56%
-10.56%
The four-week dividend-adjusted underperformance versus SP500 is 10.56%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 3.18%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 5.18%.
Mkt Cap in $bn
1.22
1.22
With a market capitalization <$2bn, INTELLIA THERAPEUTICS is considered a small-cap stock.
G/PE Ratio
1.25
1.25
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
-3.50
-3.50
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
4.37%
4.37%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
21
21
Over the last seven weeks, an average of 21 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
169
169
For 1% of index variation, the stock varies on average by 1.69%.
Correlation
0.38
0.38
Stock movements are strongly independent of index variations.
Value at Risk
8.45
8.45
The value at risk is estimated at USD 8.45. The risk is therefore 74.40%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
30.04.2021
30.04.2021